Background -Antibodies against chromo-
In most cystic fibrosis centres the occurrence of Pseudomonas aeruginosa strains resistant to ,B-lactam antibiotics is a common problem in patients with chronic P aeruginosa lung infection."2 The most important resistance mechanism consists of large amounts of chromosomal ,B-lactamase produced by stably derepressed P aeruginosa strains, as shown previously in our population with cystic fibrosis.34 These strains are selected in vivo by antibiotic pressure.56 Besides this mechanism, the permeability barrier and the drug efflux mechanisms are also involved in the development of resistance to f-lactam antibiotics.78 While these two mechanisms mainly explain the intrinsic resistance of P aeruginosa to a wide array of antimicrobial agents including 1-lactams,9 the production of chromosomal 3-lactamase is mainly responsible for the high levels of resistance to Plactam antibiotics encountered in strains collected from patients who have been intensively treated with ureidopenicillins and third generation cephalosporins.8
High levels of 13-lactamase activity have been found in the sputum of patients with cystic fibrosis,'0 which could lead to inactivation of f-lactam antibiotics. Antibodies against the chromosomal P aeruginosa ,B-lactamase (apab) have been detected in the serum and sputum of patients with cystic fibrosis and chronic lung infection with P aeruginosa. " The presence in the serum of both r-lactamase activity and alab has led to several hypotheses on their clinical significance. One theory emphasises the potential protective role of the a,Bab antibodies by inhibiting the extracellular 1-lacta*nase and thus improving the effect of the 1-lactam antibiotics. However, another hypothesis emphasises the possible destructive role of these antibodies by participating with the extracellular 3-lactamase in immune complexes which could play an important part in the pathogenesis ofairway injury in cystic fibrosis by mediating type III hypersensitivity inflammatory reactions. '2 We have previously shown that ajab antibodies are markers of the development of re- The following definitions were used to describe the patients with regard to P aeruginosa infection: non-infected (CF -P) were patients without growth of P aeruginosa in their sputum at the regular monthly examinations and with no increase in serum antibodies to P aeruginosa (less than two precipitin bands against P aeruginosa sonicated antigen); and chronically infected (CF + P) were patients in whom P aeruginosa was present in the sputum at each monthly examination for more than six months or who had more than two precipitin bands. ' years (median 10 years). The CF+P samples covered the pre-infection period and the early and late stages of chronic P aeruginosa infection. Seven of the 43 CF + P patients had chronic infection with a sensitive strain, a resistant strain being only intermittently isolated. From the 36 patients chronically infected with a resistant strain, nine had poor lung function and nine had good lung function. These were matched for age at the onset of the chronic infection and intensity of the treatment with 13-lactam antibiotics. The rest of the patients with CF + P had intermediate lung function. Since 1976 all the chronically infected patients with cystic fibrosis have been admitted to the centre every third month for a two week intravenous course of antipseudomonal antibiotics consisting of a combination of tobramycin and a f-lactam antibiotic.20 HEALTHY CONTROLS In order to establish normal values for the assay, serum samples from 39 consecutive healthy controls with no history of P aeruginosa infection were investigated. The median age (range) for 20 children was 11*7 years (1*1-18-7) and for 19 adults was 27 years (18-53 years).
P-LACTAMASE AND MURINE MONOCLONAL
ANTIBODIES f-lactamase from P aeruginosa was produced and purified as reported previously.'3 Monoclonal antibodies were made and antibodies from clone 3G2A11F7/07-1993 were used for the experiments. " 13
SDS-PAGE AND IMMUNOBLOTTING
All the serum samples were tested by immunoblotting. Purified P-lactamase was subjected to sodium dodecylsulphate-polyacrylamide gel electrophoresis (SDS-PAGE) on a 12 * 5 % acrylamide running gel and 5 % stacking gel.2' Samples were denatured before loading by heating to 1 00°C for five minutes with an equal quantity of sample buffer containing 2-5% w/v SDS. The loading of P-lactamase was 6-84 ,ug To determine the lower level of detection of serum antibodies, doubling dilutions of the standard serum were allowed to react with 0i2 cm strips of nitrocellulose paper loaded with P-lactamase equivalent to 0-2 ng protein/ mm. At each dilution the density of the bands decreased until, at a dilution of 1:150 000, no band was visible. The highest dilution at which a reaction could be seen was 1:75 000.
The sensitivity of this immunoblotting assay, expressed as the ratio between the serum quantity and the area on which the serum reacts, was 0-006 p1//cm2. By comparison, the sensitivity of the immunoblotting assay to detect antibodies against P aeruginosa sonicate (standard antigen) was 0-014 Rg/cm2,2' which illustrates the high sensitivity of our assay.
Isolation of serum IgG3 from six patients with IgG3 aab and three patients without IgG3 a,Bab as detected by immunoblotting was performed. The serum samples were delipidated (with 0-4% dextrane sulphate and calcium chloride) and applied to a protein A-Sepharose CL-4B, cyanogen bromide activated column (Sigma, St Louis, Missouri, USA) (binding buffer 3-3M NaCl, 0-15M glycine, pH 8-5; elution buffer O 1 M citrate buffer, pH 2 7; neutralising buffer 1 M Tris, pH 9). The unbound fraction containing human IgG3 and the elution fraction containing the other subclasses were analysed for the presence of apab by immunoblotting. No differences were detected between the IgG3 al3ab levels in the whole serum and the IgG3 fraction. This excluded the possibility of a false negative IgG3 result caused by a competitive inhibition by the other IgG subclasses.
ANTIBODY DETERMINATION BY ELISA
Measurements of IgG apab and of antibodies against P aeruginosa sonicate by ELISA in the same group of patients have been published previously. 13 25 
REPRODUCIBILITY OF THE IMMUNOBLOTTING ASSAY
The intraday and day-to-day variation were determined after blotted strips were allowed to react with 10 serum samples of low (n = 4), medium (n = 3), and high (n = 4) antibody concentration. Variation was calculated using the formula SD = /Id2/2n where SD is the standard deviation, d2 is the sum of squared differences of double determinations of the same sample, and n is the number of samples.
The intraday variations of the antibody titres of IgGj, were 13%, 5%, 12%, and 18%, and the day-to-day variations were 14%, 11%, 17%, and 11%, respectively. 0  6  05-1  29  9  3  11  1-1 5  35  11  6  23  1-5-2  37  23  9  28  2-3  60  29  11  52  3-4  71  37  14  60  4-5  83  43  14  66  5-7  89  43  14  76  7-9  96  54  16  79  9-11  100  56  16 after 11 years of chronic infection. IgG2 and IgG3 subclasses were detected in 56% and 16% of the patients, respectively. These results are shown in the table.
The IgG, and IgG4 apab appeared first, with more than 50% of the patients being IgG, and IgG4 positive within 2-3 years after the onset of the chronic infection. It took seven years to develop IgG2 antibodies in 50% of the patients and IgG3 antibodies developed in only 16% of the patients.
During the 11 year period of the study the median IgG antibody levels increased 22-fold, IgG, 100-fold, IgG2 22-fold, IgG4 45-fold, and IgG3 median remained zero (fig 2) . IgG3 al3ab were present in only six patients with cystic fibrosis, and all of them became positive in the first three years following the start ofthe chronic infection. The levels in this group of patients increased 16-fold during the 11 year period of the study.
The IgG alab levels measured by immunoblotting showed a statistically significant correlation with apab levels determined by ELISA from these patients (r>0-5, p <0_01). earlier than in the patients with poor lung function. The levels of apab antibodies were significantly higher in the group of patients with good lung function after 1 5-2 years (p<005), 2-3 years (p=001), and 3-4 years (p<001) from the onset of the chronic infection. The difference was not significant in the later stages of the infection. The levels of IgG a,Bab subclasses were also higher in the patients with good lung function but the difference between the two groups of patients did not reach statistical significance. In contrast, median levels of IgG antibodies against P aeruginosa sonicate (standard antigen) were significantly higher in the patients with poor lung function than in those with good lung function after 4-5 years (p<0001) and 5-7 years (p=0 5) (fig 3) .
Discussion
A general increase in all subclasses of IgG antibodies against chromosomal P aeruginosa P-lactamase was found during the chronic infection of the lungs of patients with cystic fibrosis.
The predominant response against the chro- Another important and surprising observation of our study is the early and high a pab response in patients with good lung function compared with those with poor lung function. This is in direct contrast to that previously observed for antibodies against P aeruginosa sonicate antigen where high levels were correlated significantly with poor lung function. This suggests that patients with an early production of afab are probably able to inhibit the extracellular 1-lactamase activity. Inhibition of P-lactamase activity in biofilms by mono- clonal antibodies has been shown by our group (unpublished results). The inhibition of ,B-lactamase by af3ab would lead to the protection of the P-lactam antibiotic from enzymatic hydrolysis which may result in more efficacious antipseudomonal treatment. The good lung function in the group ofpatients with high apab levels may therefore be a consequence of in vivo protection by 1-lactamase antibodies. In vitro experiments investigating this hypothesis are in progress at our laboratory.
In conclusion, the a,Bab antibodies appear to have a protective role in patients who develop them early in the course of the chronic infection with P aeruginosa, by inhibiting the extracellular P-lactamase activity.
The prevalence of IgG1 and IgG4 suggests a minor role for the apab subclass of antibodies in the immune complex mediated injury of the airway of patients with cystic fibrosis.
Further studies are required to clarify the function and activity of the a3ab antibodies in patients with cystic fibrosis and chronic infection of the lung with P aeruginosa. 
